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Background. Cognitive deﬁcits are well documented in ecstasy (3,4-methylenedioxymethamphetamine; MDMA)
users, with such deﬁcits being taken as evidence of dysregulation of the serotonin (5-hydroxytryptamine; 5-HT) system.
More recently neuroimaging has been used to corroborate these deﬁcits. The present study aimed to assess multitasking
performance in ecstasy polydrug users, polydrug users and drug-naive individuals. It was predicted that ecstasy
polydrug users would perform worse than non-users on the behavioural measure and this would be supported by
differences in cortical blood oxygenation.
Method. In the study, 20 ecstasy-polydrug users, 17 polydrug users and 19 drug-naive individuals took part. On day 1,
drug use history was taken and questionnaire measures were completed. On day 2, participants completed a 20-min
multitasking stressor while brain blood oxygenation was measured using functional near infrared spectroscopy (fNIRS).
Results. There were no signiﬁcant differences between the three groups on the subscales of the multitasking stressor. In
addition, there were no signiﬁcant differences on self-report measures of perceived workload (NASA Task Load Index).
In terms of mood, ecstasy users were signiﬁcantly less calm and less relaxed compared with drug-naive controls. There
were also signiﬁcant differences at three voxels on the fNIRS, indicating decreased blood oxygenation in ecstasy users
compared with drug-naive controls at voxel 2 (left dorsolateral prefrontal cortex), voxel 14 and voxel 16 (right dorso-
lateral prefrontal cortex), and compared with polydrug controls at V14.
Conclusions. The results of the present study provide support for changes in brain activation during performance of
demanding tasks in ecstasy polydrug users, which could be related to cerebral vasoconstriction.
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Introduction
Recreational drug use is argued to be detrimental to
normal physiological and psychological functioning.
Various studies have found cognitive deﬁcits in ec-
stasy/3,4-methylenedioxymethamphetamine (MDMA)
users (Parrott & Lasky, 1998; Wareing et al. 2004;
Montgomery et al. 2010). While some studies have
shown deﬁcits in executive functioning (Fisk et al.
2004; Montgomery et al. 2005), a number of recent
reviews have shown that the most prominent and per-
sistent deﬁcits are in learning and memory, particu-
larly verbal recall (Kalechstein et al. 2007; Zakzanis
et al. 2007; Gouzoulis-Mayfrank & Daumann, 2009).
The acute psychological and physiological effects
are thought to result primarily from serotonin and
dopamine agonism (McDowell & Kleber, 1994), with
repeated exposure purported to damage serotonin
neurons resulting in problems with cognition, sleep
and mood (Parrott et al. 2000; Parrott, 2013). In animal
studies MDMA administration mirroring human rec-
reational doses has a deleterious effect on serotonergic
neurons (Green et al. 1995). Such serotonergic neuro-
toxicity is a possibility in humans, especially with
higher nightly doses (McCann et al. 1994). Moreover,
the neuronal areas implicated in working memory
and executive functioning are often observed to be lo-
calized in the dorsolateral prefrontal cortex (DLPFC)
(Curtis & D’Esposito, 2003). These structures are den-
sely innervated with serotonin (5-hydroxytryptamine;
5-HT) receptors (Pazos et al. 1987), thus serotonergic
neurotoxicity or down-regulation may result in cogni-
tive deﬁcits speciﬁc to functions that these areas
maintain (Reneman et al. 2006; Montgomery & Fisk,
2008).
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Neuroimaging techniques [electroencephalography
(EEG), functional magnetic resonance imaging (fMRI),
functional near infrared spectroscopy (fNIRS)] are
increasingly used in drug research to provide neuro-
physiological correlates of behavioural deﬁcits, or
indeed perhaps as a more sensitive measure of cogni-
tive impairment. For example, Burgess et al. (2011)
assessed ecstasy users’ performance on verbal and
non-verbal recognition memory, with event related
potential (ERP) measures compared with two control
groups (drug-naive participants and polydrug users
who do not use ecstasy). Ecstasy users displayed
abnormalities in an ERP component associated with
recollection of words but not faces, despite equivalent
behavioural performance. Similarly, Kanayama et al.
(2004) observed fMRI differences in cannabis users
compared with controls during a spatial working
memory task despite the absence of behavioural differ-
ences. Bosch et al. (2013) have also shown a direct link
between brain glucose metabolism in the DLPFC and
level of MDMA use. MDMA users were impaired rela-
tive to controls on the Rey Auditory Verbal Learning
Test (RAVLT) and showed signiﬁcantly decreased
glucose metabolism in various brain areas including
the right hippocampus, bilateral DLFPC, bilateral
thalamus and inferior parietal cortex. In the MDMA
users, positive correlations were observed between
glucose metabolism in the prefrontal and parietal
areas and RAVLT performance. Importantly, lifetime
MDMA dose was signiﬁcantly negatively related to
glucose metabolism in the left DLPFC. These studies
highlight the importance of investigating brain indices
of cognitive performance in addition to behavioural
indices.
The present study employed fNIRS. fNIRS is a novel,
non-invasive, optical neuroimaging technique that is
portable and is used to measure the haemodynamic re-
sponse to brain activation (Leff et al. 2011). Typically,
fNIRS will penetrate to structures around 2–3mm of
the cortex underlying the skull (Firbank et al. 1998).
Therefore forebrain structures such as the DLPFC can
be easily accessed and observed. Activation of the
DLPFC is prominent in higher-level processing, and
due to these structures being easy to access with this
type of imaging, it has been used in several studies ob-
serving motor control and learning (Leff et al. 2011),
as well as more complex tasks that involve working
memory and category discrimination (Izzetoglu et al.
2004). Generally, an increase in the chromophore
Hbo2 (oxyhaemoglobin) coupled with a decrease in
Hhb (deoxyhaemoglobin) is accepted as being reﬂec-
tive of activation to a certain brain region (Ehlis et al.
2008; Leff et al. 2008, 2011), and the distribution of
this response is regionally speciﬁc. Thus, the cortical
regions underlying certain optodes of the fNIRS
headset are understood to be responsible for the
observed response (Leff et al. 2011).
Although currently there remains a paucity of
studies conducted with fNIRS and substance use
(speciﬁcally ecstasy/MDMA use), it has been used in
other populations with working memory problems.
Ehlis et al. (2008) observed a signiﬁcant reduction in
Hbo2 over ventrolateral prefrontal cortex channels
in attention-deﬁcit/hyperactivity disorder (ADHD)
patients compared with controls in relation to a work-
ing memory N-back task. It was argued that this
reﬂects a reduction in activation of this area of the
brain during task performance. Interestingly, this
was not accompanied by signiﬁcant behavioural differ-
ences (although a trend was observed). Similarly,
Schecklmann et al. (2008) reported a lower concen-
tration of Hbo2 in ADHD patients relative to controls
during two versions of a verbal ﬂuency task, suggest-
ing that executive functioning deﬁcits are associated
with decreased oxygenation to the brain areas that
underlie performance of these tasks.
The present study aims to investigate changes in pre-
frontal blood oxygenation in response to a demanding
task in ecstasy users, polydrug users and non-users.
The cerebral haemodynamic response to conducting
several tasks at once will be measured as well as beha-
vioural performance. It is hypothesized that ecstasy
users will perform worse on the multitasking stressor
and fNIRS will provide corollary data of this by dis-
playing a reduction in oxygenated haemoglobin in
comparison with the control groups.
Method
Design
For behavioural and fNIRS analysis a between-groups
design was used, with a between-groups factor of drug
user group with three levels (ecstasy user, polydrug
user and drug-naive controls). Univariate analysis of
variance (ANOVA) was conducted on the behavioural
data with the total scores on each component of the
task as the dependent variables (Stroop, mental arith-
metic, tracking/target area – visual monitoring and
warning/rising bars – visual monitoring). fNIRS data
were analysed using univariate ANOVA with mean
oxygenated haemoglobin at each voxel measured as
the dependent variables (voxels 1–16; V1–V16). Any
signiﬁcant main effects were further investigated
using Tukey’s honestly signiﬁcant difference test.
Participants
A total of 20 ecstasy users (mean age 21.61, S.D.=0.52
years; 12 male), 17 non-ecstasy polydrug user controls
(mean age 21.23, S.D. =0.79 years; 12 male) and
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19 drug-naive controls (mean age 21.60, S.D.=0.84
years; six male) were recruited via direct approach to
Liverpool John Moores University students. For in-
clusion in the study participants had to be aged be-
tween 18 and 29 years. For inclusion in the ecstasy/
MDMA user group, participants must have used ec-
stasy/MDMA on at least ﬁve occasions over their life-
time (actual minimum=seven tablets) but may have
used a range of substances in addition to MDMA. To
be included in the non-ecstasy polydrug user group,
participants must have consumed illicit drugs on at
least three occasions in the last 12 months, but never
have consumed ecstasy/MDMA, and ﬁnally for in-
clusion in the drug-naive control group participants
must have never consumed any illicit drugs. All parti-
cipants were asked to abstain from consuming ecstasy
for a minimum of 7 days prior to testing. Participants
were also requested to abstain from use of other illicit
drugs for a minimum of 24 h prior to participating and
ideally 7 days.
Materials
A background drug use questionnaire (Montgomery
et al. 2005) was administered. Estimates of total lifetime
drug use of each drug were calculated (according to
Montgomery et al. 2005) as well as totals for drug use
over the last 30 days and weekly drug use estimates.
State Anxiety Inventory – Visual Analogue Scale
(SAI-VAS)
The SAI-VAS was completed pre- and post-testing
period. This comprises six statements (I feel calm,
I feel tense, I feel upset, I feel relaxed, I feel content,
I feel worried) and participants have to indicate on a
100mm line how much they agree with the statement,
ranging from 0 – not at all, to 100 – very much.
Multitasking stress test
The multitasking framework (Purple Research Sol-
utions, UK) is a personal computer (PC)-run platform
used to elicit acute psychological stress (Wetherell &
Sidgreaves, 2005). The same combination of four stres-
sor modules (Stroop, mental arithmetic, tracking/target
area – visual monitoring, and warning/rising bars –
visual monitoring) was used for all participants, at a
medium-intensity workload. The task requires partici-
pants to attend to the four different components/
modules of the task simultaneously. The set of tasks
includes a mental arithmetic task whereby participants
are required to calculate a series of 2×3 digit addition
sums; visual monitoring (target area) whereby partici-
pants must monitor the position of a moving cursor
and reset this cursor when it enters a points zone; a
second visual monitoring module (rising bars) com-
prises of a set of six bars that rise towards a target
line at varying speeds. Once the bars have reached
the target, participants must select the order in which
the bars reached the target, fastest ﬁrst. Finally, a
Stroop task module involves colour names appearing
onscreen in various colours; participants must cor-
rectly select the colour the word appears in, rather
than the written word. For more information on the
different modules of the framework, see Wetherell &
Sidgreaves (2005).
Equipment
Haemodynamic response to task was monitored using
a continuous-wave fNIRS system developed by Drexel
University (Philadelphia, PA) and supplied by Biopac
Systems (USA). The fNIR sensor has a temporal resol-
ution of 500ms per scan (2Hz), with a source-detector
separation of 2.5 cm allowing 1.25 cm penetration
depth (Ayaz et al. 2012). An fNIR100 control box and
data acquisition and visualization software COBI
studio (Drexel University) were used during data col-
lection (according to Ayaz et al. 2011, 2012) with a
serial cable between display and acquisition PCs to
identify task markers.
Procedure
Participants were required to attend the laboratory on
two occasions. On Time 1, upon entering the labora-
tory participants were informed of what the study
would entail and written consent was obtained. Parti-
cipants were given the background drug use question-
naire and an assessment of ﬂuid intelligence [Raven’s
Progressive Matrices (RPM); Raven et al. 1998] to com-
plete. On Time 2, a pre-task SAI-VAS was given upon
entering the laboratory. After this the fNIRS sensor
pad was attached to the participants’ forehead whilst
they read instructions on how to complete the task.
Participants then completed an easy 2-min practice
trial of the task. The fNIRS signals were displayed on
a desktop computer running COBI studio (Drexel Uni-
versity) in an room adjacent to the testing room. Pro-
viding the signals from the fNIRS were stable, a
baseline of inactivity was recorded before the partici-
pants were instructed to complete a 20-min session of
the multitasking stressor task on a desktop computer
running the purple framework (Purple Solutions,
UK). After the 20min had elapsed, participants com-
pleted a post-task SAI-VAS. The NASA Task Load
Index (TLX; Hart et al. 1988) was completed post-task
to measure perceived workload. Finally, participants
were debriefed and paid £20 in store vouchers.
The study was approved by Liverpool John Moores
University Research Ethics Committee, and was
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administered in accordance with the ethical guidelines
of the British Psychological Society.
fNIRS analysis
fNIRS raw data from COBI studio were pre-processed
using fNIRSOFT (Ayaz, 2010). All 16 optodes (oxy-
and deoxyhaemoglobin) were visually inspected for
any saturated channels, and any saturated channels
were discarded. A high-pass ﬁlter (0.1 Hz cut-off)
and a linear-phase ﬁlter (order of 20) were used to re-
move high-frequency noise and noise due to respir-
ation (Ayaz et al. 2011, 2012). Using the modiﬁed
Beer–Lambert law logarithm in fNIRSOFT (Ayaz,
2010), we calculated total blood oxygenation, deoxy-
genation and volume changes relative to baseline
over the entire epoch for the 16 channels.
Results
RPM scores and pre- and post-task SAI-VAS scores are
displayed in Table 1. Indices of other drug and alcohol
use are displayed in Table 2.
One-way ANOVA revealed that there were no sig-
niﬁcant between-group differences on age and ﬂuid
intelligence (p>0.05 in both cases). Pre- and post-task
SAI-VAS scores for each of the six subscales (calm,
tense, relaxed, content, upset and worried) were ana-
lysed using a mixed ANOVA, with user group as the
between-subject factor and time point (pre/post) as
the within-subjects factor. For ‘calm’ there was no sig-
niﬁcant main effect of time point (F1,53 =0.19, p>0.05)
and no time point×group interaction (F2,53 =1.97,
p>0.05), but there was a main effect of group (F2,53 =
3.08, p40.05). Pairwise comparisons showed
that ecstasy users felt less calm than both other
groups (p<0.05). For ‘tense’ there was a signiﬁcant
main effect of time point (F1,53 =3.95, p40.05), with
ecstasy and polydrug users showing increases at
Time 2, but no time point×group interaction (F2,53=
0.32, p>0.05), and no main effect of group (F2,53 =
1.75, p>0.05). ‘Upset’ showed no main effect of
time point (F1,53=1.69, p>0.05), no time point×group
interaction (F2,53 =1.82, p>0.05) and no main effect
of group (F2,53 =0.07, p>0.05). ‘Relaxed’ also showed
no main effect of time point (F1,53 =0.03, p>0.05) and
no time point×group interaction (F2,53=0.05, p>0.05),
but did show a signiﬁcant main effect of group
(F2,53=3.04, p40.05). Pairwise comparisons revealed
that drug-naive controls were signiﬁcantly more rela-
xed than ecstasy users (p<0.05). ‘Content’ revealed
no signiﬁcant effect of time point (F1,53=0.25, p>0.05),
no time point×group interaction (F2,53=0.33, p>0.05),
and no main effect of group (F2,53 =1.39, p>
0.05). Finally, ‘worried’ revealed a main effect of time
point (F2,53 =3.04, p40.05), with worry being greatest
pre-task, but no time point×group interaction (F2,53 =
0.27, p>0.05), and no main effect of group (F2,53 =
1.06, p>0.05).
ANOVA revealed a between-group difference in the
amount of alcohol consumed (weekly) (F2,52=3.28, p<
0.05). Pairwise comparisons revealed that the ecstasy
users drank signiﬁcantly more than drug-naive con-
trols (p40.05).
Behavioural data analysis
The multitasking stressor task was developed by
Purple Solutions (UK) and performance was analysed
Table 1. Fluid intelligence and mood variables
Ecstasy users Polydrug controls Drug-naive controls
Raven’s Progressive Matrices, no.
correct out of a maximum of 60
49.70 (5.12) 51.82 (5.42) 49.58 (6.94)
SAI-VAS pre-task calm 63.80 (24.25) 84.06 (10.29) 79.00 (19.44)
SAI-VAS post-task calm 70.00 (17.27) 74.24 (30.68) 78.37 (20.28)
SAI-VAS pre-task tense 20.30 (15.89) 15.71 (19.09) 16.14 (16.84)
SAI-VAS post-task tense 25.10 (15.97) 22.35 (24.89) 14.32 (16.24)
SAI-VAS pre-task upset 11.70 (9.59) 14.65 (23.17) 11.00 (11.69)
SAI-VAS post-task upset 12.50 (9.55) 8.00 (9.97) 10.37 (10.65)
SAI-VAS pre-task relaxed 66.05 (20.35) 68.29 (28.76) 79.47 (16.52)
SAI-VAS post-task relaxed 64.30 (17.93) 69.00 (29.54) 78.89 (16.70)
SAI-VAS pre-task content 71.60 (16.54) 76.76 (21.33) 74.21 (24.67)
SAI-VAS post-task content 71.25 (11.84) 82.00 (14.90) 73.89 (21.21)
SAI-VAS pre-task worried 22.40 (17.27) 19.12 (24.76) 14.79 (17.69)
SAI-VAS post-task worried 19.70 (12.68) 13.71 (17.75) 12.37 (13.80)
Data are given as mean (standard deviation).
SAI-VAS, State Anxiety Inventory –Visual Analogue Scale.
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using SPSS (version 20; IBM, USA). Due to eight parti-
cipants (four ecstasy users, three polydrug users and
one drug-naive control) not following instructions cor-
rectly on the Stroop task and consistently answering
incorrectly on the task, their data on this component
on the task were not analysed any further. These par-
ticipants were also excluded from fNIRS analysis.
Performance data can be observed in Table 3.
There were no signiﬁcant differences between
groups on any of the components of the task: Stroop
(F2,45 =0.08, p>0.05); Maths (F2,53=0.56, p>0.05);
Tracking/target visual monitoring (F2,53 =0.50, p>0.05).
Levene’s statistic was violated on the warning/
rising bars scores, therefore an independent-samples
Kruskall–Wallis test was conducted. This revealed
that there were no signiﬁcant differences between ec-
stasy users (rank=560), polydrug controls (rank=570)
and drug-naive controls (rank=580) on this component
of the task (H2=1.43, p>0.05). On the composite total
score, ANOVA revealed no signiﬁcant between-group
differences (F2,45=0.55, p>0.05).
Post-task NASA TLX scores were analysed using
multivariate ANOVA (MANOVA). This revealed
no overall between-group differences in task load
(F12,96=1.25, p>0.05) for Pillai’s trace, nor any
between-group differences on the individual subscales
(Mental demand: F2,52 =1.32, p>0.05; Physical demand:
F2,52 =0.11, p>0.05; Temporal demand: F2,52 =0.10, p>
0.05; Effort: F2,52=1.97, p>0.05; Performance: F2,52=
2.39, p>0.05; Frustration: F2,52=2.65, p>0.05).
fNIRS analysis
Averaged oxygenated and deoxygenated haemoglobin
changes from baseline are displayed in Figs. 1 and 2.
A series of ANOVAs1† were used to assess group
differences in changes from baseline. This analysis
was conducted due to large concentration increases
in oxygenated haemoglobin and decreases in
Table 2. Indices of drug use
Ecstasy users Polydrug controls Drug-naive controls
Mean (S.D.) n Mean (S.D.) n Mean (S.D.) n
Ecstasy
Frequency, times per week 0.22 (0.21) 20 – – – –
Recent use: last 30 days, tablets 2.00 (3.42) 20 – – – –
Total lifetime use, tablets 253.86 (376.20) 20 – – – –
Cannabis
Frequency, times per week 2.74 (2.81) 20 1.11 (1.56) 16 – –
Recent use: last 30 days, joints 46.56 (59.89) 17 19.34 (46.36) 16 – –
Total lifetime use, joints 3613.80 (4469.70) 20 1562.96 (3021.05) 17 – –
Cocaine
Frequency, times per week 0.06 (0.08) 2 0.05 (0.06) 2 – –
Recent use: last 30 days, g 0.00 (0.00) 2 0.00 (0.00) 2 – –
Total lifetime use, g 415.00 (43.84) 2 7.50 (0.71) 2 – –
Ketamine
Frequency, times per week 0.19 (0.19) 5 – – – –
Recent use: last 30 days, g 0.00 (0.00) 5 – – – –
Total lifetime use, g 21.72 (16.90) 5 – – – –
Mephedrone
Frequency, times per week 0.21 (0.16) 4 0.16 (0.27) 3 – –
Recent use: last 30 days, g 0.00 (0.00) 4 0.00 (0) 3 – –
Total lifetime use, g 63.45 (57.60) 4 23.67 (17.39) 3 – –
Amphetamine
Frequency, times per week 0.13 (0.09) 3 0.04 1 – –
Recent use: last 30 days, g 0.00 (0.00) 3 0.00 (0) 1 – –
Total lifetime use, g 14.00 (9.64) 3 55.00 1 – –
Alcohol, UK units per week 13.20 (6.68) 20 12.44 (9.70) 16 6.99 (8.14) 19
S.D., Standard deviation.
† The notes appear after the main text.
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deoxygenated haemoglobin being understood to rep-
resent increased levels of neurological activation
(Hoshi et al. 2001; Cui et al. 2010; Ayaz et al. 2011)
and also due to each voxel theoretically relating to a
different brain region.
ANOVA revealed signiﬁcant between-group
differences in average oxyhaemoglobin changes at
V2 (F2,43=4.78, p<0.05), V14 (F2,43 =6.37, p<0.01) and
V16 (F2,42=3.32, p<0.05). There were no signiﬁcant
between-group differences at any of the other voxels
measured (p>0.05).
Pairwise comparisons revealed that at V2 ecstasy
users showed a signiﬁcantly reduced oxyhaemoglobin
change compared with drug-naive controls (p<0.05).
At V14 ecstasy users showed signiﬁcantly lower
oxyhaemoglobin than both polydrug controls (p<
0.01) and drug-naive controls (p<0.05). At V16 ecstasy
users again showed signiﬁcantly lower oxyhaemo-
globin than drug-naive controls (p<0.05).
ANOVA on deoxyhaemoglobin changes from base-
line revealed signiﬁcant between-group differences
at V1 (F2,42 =3.96, p<0.05), V2 (F2,43=4.71, p<0.05),
V4 (F2,30 =3.66, p<0.05), V12 (F2,30=5.04, p<0.05) and
V14 (F2,43 =5.09, p<0.01). There were no signiﬁcant
between-group differences at any of the other voxels
measured (p>0.05).
Pairwise comparisons revealed that at V1, polydrug
controls showed signiﬁcantly greater deoxyhaemoglo-
bin than drug-naive controls (p<0.05), and this differ-
ence approached signiﬁcance compared with ecstasy
users (p=0.07). At V2, polydrug controls showed sig-
niﬁcantly greater deoxyhaemoglobin increase than
ecstasy users (p<0.05) and this difference approached
signiﬁcance compared with drug-naive controls (p=
0.08). At V4 polydrug controls showed signiﬁcantly
increased deoxyhaemoglobin compared with drug-
naive controls (p<0.05). At V12 polydrug controls
showed signiﬁcantly increased deoxyhaemoglobin
compared with both ecstasy users and drug-naive con-
trols (p<0.05 in both cases) and at V14 polydrug con-
trols showed signiﬁcantly greater deoxyhaemoglobin
compared with ecstasy users (p<0.01). Ecstasy users
and drug-naive controls did not differ signiﬁcantly
from each other at any of these voxels.
Table 3. Performance data for the four tasks
Ecstasy users Polydrug controls Drug-naive controls
Stroop 4443.75 (1653.38) 4222.14 (1683.38) 4500.28 (2545.14)
Warning 550.50 (43.71) 566.47 (28.93) 533.16 (141.07)
Tracking 392.80 (112.39) 437.29 (58.23) 386.11 (203.88)
Maths 414.35 (235.65) 463.65 (230.06) 371.05 (293.16)
Total 5847.75 (1721.07) 5691.29 (1727.09) 6382.22 (2357.42)
Data are given as mean (standard deviation).
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Fig. 1. Mean oxyhaemoglobin (oxy-Hb) change (μmolar) from baseline during the entire multitasking epoch (20min) for
ecstasy users, polydrug controls and drug-naive controls. ** Signiﬁcantly different from polydrug controls (p<0.01).
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These results show a general blunted increase in
oxygenated haemoglobin during the tasks for ecstasy
users relative to drug-naive controls at V2, V14 and
V16. Ecstasy users also displayed signiﬁcantly reduced
oxyhaemoglobin change at V14 compared with poly-
drug controls. Furthermore, as to be expected due to
a general inverse correlation between oxygenated and
deoxygenated haemoglobin usually observed in neuro-
logical activity, ecstasy users showed a signiﬁcantly
reduced decrease in deoxygenated haemoglobin com-
pared with drug-naive controls at V1, and relative to
polydrug controls at V2, V12 and V14.
Relationship between cortical blood changes and
drug use
To assess the relationship between the changes in cor-
tical blood ﬂow observed using fNIRS and parameters
of drug use, we used Spearman’s correlations. Results
are displayed in Table 4; all correlations were eval-
uated at p<0.01 to adjust for multiple comparisons
(Sankoh et al. 1997).
There were a number of signiﬁcant correlations be-
tween ecstasy use and oxygenation change. Notably,
frequency of use was signiﬁcantly correlated with V2
(left inferior DLPFC), V6 and V8 (left inferior mid pre-
frontal cortex) and V14 (right inferior DLPFC), total
lifetime dose with V2 (left inferior DLPFC), V6 and
V8 (left inferior mid prefrontal cortex) and V14 and
V16 (right inferior DLPFC), while amount used in
the last 30 days was signiﬁcantly correlated with V2
and V4 (left inferior DLPFC), V8 (left inferior mid
prefrontal cortex) and V14 and V16 (right inferior
DLPFC). There were two signiﬁcant correlations with
indices of drug use, with frequency of cannabis use
correlated with V8 and frequency of cocaine use with
V14. In both cases the correlations were weaker than
those for ecstasy. For deoxygenation change, total life-
time dose of ecstasy was signiﬁcantly correlated with
V14 (right inferior DLPFC).
Discussion
The aim of the current study was to investigate the
effects of ecstasy use on a multitasking stress test and
to assess drug-related differences in haemodynamic re-
sponse to task. The ecstasy users in this study did not
differ signiﬁcantly from controls on background vari-
ables such as perceived stress, ﬂuid intelligence or
age. Nor did they differ signiﬁcantly on any of the in-
dividual components that made up the multitasking
stressor task, or on perceived workload as measured
by the NASA TLX. There were, however, differences
on subscales of the SAI-VAS, indicating that ecstasy
users felt less calm than both other groups overall
and less relaxed than drug-naive controls. Further-
more, as to be expected, all groups were less worried
post-task.
Despite an absence of between-group differences on
behavioural measures, the fNIRS data revealed several
signiﬁcant differences that are worthy of discussion.
Ecstasy users displayed a signiﬁcant reduction in oxy-
genated haemoglobin compared with both polydrug
users and drug-naive controls at V14 pertaining to
the inferior side of the right DLPFC. At V2 and V16, ec-
stasy users had signiﬁcantly smaller change in oxyge-
nated haemoglobin relative to drug-naive controls.
V2 relates to the inferior side of the left DLPFC, and
V16 relates to the inferior side of the right DLPFC.
As such, the results imply reduced activation of the
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Fig. 2. Mean deoxyhaemoglobin (deoxy-Hb) change (μmolar) from baseline during the entire multitasking epoch (20min) for
ecstasy users, polydrug controls and drug-naive controls. Signiﬁcantly different from polydrug controls: * p<0.05, ** p<0.01.
† Signiﬁcantly different from drug-naive controls (p<0.05). V, Voxel; DLPFC, dorsolateral prefrontal cortex; PFC,
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DLPFC in ecstasy users that is bilateral. A blunted de-
crease of deoxygenated haemoglobin in ecstasy users
compared with drug-naive controls at V1 and relative
to polydrug controls at V2 and V12 are also suggestive
of similar differential functioning between ecstasy
users and controls over the left DLPFC area. Fur-
thermore, V12 pertains to the right medial prefrontal
cortex, suggesting that MDMA’s effects on haemody-
namic response are apparent across several areas of
the prefrontal cortex. In addition to these between-
group differences, indices of ecstasy use were signiﬁ-
cantly correlated with oxygenation change in the
right and left inferior DLPFC and the inferior mid
prefrontal cortex. These correlations were negative,
suggesting that more frequent ecstasy use, a higher
lifetime dose and a larger amount used in the
30 days prior to testing were associated with a smaller
oxygenation change from baseline.
In animal studies it is well documented that MDMA
is a selective brain serotonin neurotoxin (Green et al.
2003). Moreover, the DLPFC is densely innervated
with 5-HT neurons (Curtis & D’Esposito, 2003) and if
MDMA is also a selective serotonin neurotoxin in
humans, then differential functioning of areas of the
DLPFC and the cognitive processes maintained by
these areas should be observable in ecstasy users. In
line with this, the current results suggest a differential
pattern of cognitive function in ecstasy users relative to
Table 4. Correlations with indices of drug use
Ecstasy Cannabis Cocaine
Freq Total Recent Freq Total Recent Freq Total
Oxy V1 −0.09 −0.16 0.03 −0.17 −0.03 0.11 0.16 0.06
Oxy V2 −0.33* −0.36* −0.35* −0.17 −0.14 −0.02 0.17 0.05
Oxy V3 −0.19 −0.26 −0.15 −0.14 −0.01 0.14 0.11 0.06
Oxy V4 −0.32 −0.22 −0.49* 0.00 0.12 0.13 0.17 0.10
Oxy V5 −0.15 −0.19 −0.17 −0.26 −0.12 −0.00 0.11 0.03
Oxy V6 −0.34* −0.42* −0.29 −0.13 −0.10 0.08 0.21 0.02
Oxy V7 −0.08 −0.10 −0.11 −0.02 0.07 0.14 0.02 −0.03
Oxy V8 −0.41* −0.45* −0.34* −0.33* −0.26 −0.07 0.25 0.10
Oxy V9 −0.16 −0.17 −0.19 −0.17 −0.10 0.06 0.09 0.05
Oxy V10 −0.26 −0.27 −0.26 −0.27 −0.12 −0.07 0.28 0.20
Oxy V11 −0.02 −0.11 −0.04 −0.07 0.09 0.04 0.24 0.26
Oxy V12 −0.29 −0.33 −0.33 −0.24 −0.11 −0.10 0.23 0.18
Oxy V13 −0.12 −0.17 −0.08 −0.08 0.05 0.15 0.12 0.13
Oxy V14 −0.42* −0.45* −0.38* −0.27 −0.14 −0.09 0.34* 0.11
Oxy V15 −0.07 0.14 −0.09 −0.06 0.14 0.10 0.25 0.28
Oxy V16 −0.32 −0.37* −0.32* −0.21 −0.11 −0.04 0.21 0.02
Deoxy V1 −0.06 −0.06 −0.24 0.18 0.24 0.02 0.05 0.02
Deoxy V2 −0.11 −0.19 −0.21 0.07 0.09 −0.00 −0.08 −0.15
Deoxy V3 0.19 0.17 0.01 0.29 0.21 0.14 −0.13 −0.20
Deoxy V4 0.02 0.07 −0.14 0.26 0.17 0.11 −0.11 −0.17
Deoxy V5 −0.01 0.01 −0.08 −0.07 −0.04 −0.12 −0.05 −0.07
Deoxy V6 −0.14 −0.18 −0.17 0.00 −0.04 0.10 −0.07 −0.40
Deoxy V7 0.12 0.09 −0.04 0.20 0.24 0.10 −0.07 −0.40
Deoxy V8 0.12 0.16 −0.04 0.23 0.20 0.15 −0.08 −0.03
Deoxy V9 −0.04 −0.07 −0.21 0.07 0.05 −0.04 −0.06 −0.05
Deoxy V10 0.00 0.02 −0.06 0.04 0.14 0.05 0.05 0.09
Deoxy V11 −0.15 −0.07 −0.10 0.04 −0.01 −0.01 0.11 0.04
Deoxy V12 0.21 −0.25 −0.10 −0.10 0.10 −0.03 0.26 0.30
Deoxy V13 0.17 −0.11 −0.22 0.03 −0.01 0.00 −0.03 −0.05
Deoxy V14 −0.29 −0.35* −0.27 −0.16 −0.08 −0.13 0.23 0.07
Deoxy V15 −0.17 −0.15 −0.19 0.02 0.02 −0.03 0.05 0.15
Deoxy V16 −0.09 −0.13 −0.20 −0.05 0.04 −0.06 0.04 0.13
Freq, Frequency (times per week); total, total lifetime use; recent, recent use over last 30 days; oxy, oxygenation change;
V, voxel; deoxy, deoxygenation change.
* Correlation signiﬁcant at p<0.01.
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controls that relate to areas of the DLPFC. Similar
ﬁndings from other neuroimaging studies have
also suggested impairment in ecstasy users that are
localized to areas of the prefrontal cortex. Jager et al.
(2008) observed altered brain activity patterns in re-
lation to associative learning in the left DLPFC as
well as the right middle occipital gyrus in an fMRI
study. However, it was conceded that this does not
necessarily signify serotonergic neurotoxicity; it does,
though, go some way to substantiating the idea of
widespread loss of serotonin axons with repeated use
of MDMA. Moreover, serotonergic modulation of the
DLPFC has been observed in a tryptophan depletion
study with fMRI (Evers et al. 2005), where it was
observed that behavioural reversal after tryptophan
depletion was accompanied by changes in signals pre-
senting from the right ventromedial prefrontal cortex,
as well as the dorsomedial prefrontal cortex. More re-
cently Bosch et al. (2013) have linked brain glucose
metabolism in the DLPFC to level of MDMA use,
with higher use being associated with lower levels of
glucose metabolism. MDMA users had dysfunction
in glucose metabolism in a range of brain areas
which is consistent with serotonergic neurotoxicity;
speciﬁcally, the decreases in the raphe nuclei, where
serotonergic neurons stem from, provide corollary evi-
dence of neurotoxicity/short-term degradation.
This suggests that performance on cognitive tasks
can be altered by transient depletion of serotonin in
brain regions, such as the DLPFC that relate to higher-
level cognitive tasks, such as reversal learning.
Other support for serotonergic neurotoxicity follow-
ing ecstasy use in humans comes from Kish et al. (2010)
who reported signiﬁcantly decreased serotonin trans-
porter binding in all cerebral cortices and the hippo-
campus, with the decrease related to amount of drug
use. Similar decreases in serotonin transporter (SERT)
binding in ecstasy users were reported by Erritzoe
et al. (2011) in a positron emission tomography (PET)
study. Moreover, Benningﬁeld & Cowan (2013) re-
viewed recent studies of brain imaging in ecstasy
users and concluded that recreational ecstasy use in
humans is associated with increases in the 5-HT-2A
receptors and decreases in SERT. These ﬁndings sug-
gest the neurotoxic potential of ecstasy, and given
that behavioural studies have reported performance
deﬁcits in executive functioning tasks that are main-
tained by areas highly populated with 5-HT neurons,
evidence is growing to suggest possible serotonergic
neurotoxicity in the prefrontal cortex. This idea is
further corroborated by the current study, with the ob-
servation of a differential pattern of functioning in
these areas in ecstasy users. It is important to note
that the direction of oxygenation change is not as pre-
dicted. One possible reason for this may be related to
the sympathomimetic effect of ecstasy. A number of
previous studies have noted increased vasoconstriction
in human ecstasy users not only while on the drug,
but for prolonged periods of abstinence. Chang et al.
(2000) found protracted vasoconstriction evidenced
by decreases in regional cerebral blood ﬂow (rCBF)
in dorsolateral areas of the prefrontal cortex. In
addition, Reneman et al. (2000) noted that reduced
serotonergic binding in a single photon emission
computerized tomography (SPECT) study was sig-
niﬁcantly correlated with rCBF, with low CBF (indicat-
ing vasoconstriction) associated with low binding.
Taussky et al. (2012) found a strong linear relationship
between fNIRS measurements and rCBF measure-
ments taken via perfusion computerized tomography
(CT) scanning, suggesting that fNIRS measurements
may be sensitive to the same changes in neuromicro-
vasculature. Taken together, one possible reason for
the reduction in oxygenation in ecstasy users is that
damage to the serotonin system has caused prolonged
vasoconstriction resulting in decreased rCBF in frontal
areas. Consequently, the change in oxygenation is less
pronounced as there is less blood ﬂow altogether.
The DLPFC is implicated in higher-level cognitive
functioning, and behavioural studies have shown
that ecstasy users’ performance on tasks that load on
higher-level executive functions such as memory
updating is reduced relative to controls (Montgomery
& Fisk, 2008). Moreover ecstasy-related cognitive deﬁc-
its have been observed to be increased with task/cogni-
tive load (Fisk et al. 2011). As such, the current study is
in line with previous ﬁndings of ecstasy users showing
cognitive deﬁcits with increased workload, as the
multitasking paradigm loads heavily on cognitive
functions and alterations to normal functioning of
areas of the DLPFC have been observed. The multi-
tasking framework used in the present study required
participants to perform several demanding cognitive
tasks simultaneously. It has been shown to elicit sub-
jective stress in non-users (Wetherell & Sidgreaves,
2005). To further support this, Wetherell et al. (2012)
found that recreational ecstasy/MDMA users perceive
signiﬁcantly greater time pressure and levels of
mental effort, compared with non-user controls, dur-
ing the multitasking framework. It is also noteworthy
that seven of the eight participants’ data that were
excluded from analysis of the Stroop task module,
due to incorrect interpretation of instructions, were
drug users (four ecstasy users). It has been observed
previously that ecstasy users made more errors when
completing a web-based questionnaire (Rodgers et al.
2003) than other drug users and drug-naive controls.
Therefore it is possible that there are deﬁcits in the pro-
cessing of instructional information associated with
ecstasy use.
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fNIRS, due to its speciﬁcity to the prefrontal cortex,
is useful for studies in ecstasy users as it is these frontal
structures that are densely innervated with 5-HT
neurons and are perhaps most susceptible to degra-
dation with ecstasy use. However, the level of demand
and relatively high mental workload involved in the
multitasking paradigm could require recruitment of
additional brain areas that are currently not monitored
with this device (Ayaz et al. 2012). Perhaps if this
equipment enabled coverage of the whole brain, or
indeed it was accompanied by other neuroimaging
techniques such as fMRI, a better understanding of
the underlying mechanisms could be achieved.
Future research should seek to clarify the nature of
these changes in the brain, in the absence of beha-
vioural differences.
Although there are signiﬁcant ﬁndings in the current
study in relation to ecstasy users’ CDF, as with any
study pertaining to cognitive deﬁcits and ecstasy use
certain limitations require a degree of caution when
interpreting results. Attempts were made to control
for use of other drugs with an inclusion of a polydrug
user group (namely cannabis users) that were ecstasy
naive. However, the ecstasy group used a range of
other drugs and as such it is still possible that any
observed differences could be attributable to other
drug use, or perhaps concomitant use of other drugs
with ecstasy. Nevertheless, the results from pair-
wise comparisons did show a differential pattern of
DLPFC activation in ecstasy users compared with
both control groups, which suggests that cognitive im-
pairment is observable in ecstasy-using populations. It
should also be noted that while the multitasking
framework is a good task for eliciting high mental
effort and psychological/psychobiological indices of
stress, multitasking as a function may be less reliant
on 5-HT compared with other cognitive functions
such as verbal recall (Robbins & Arnsten, 2009).
Future research should seek to investigate fNIRS para-
meters of performance utilizing verbal recall tasks.
The necessity of a quasi-experimental design in this
study can also be considered a limitation and the possi-
bility that some other individual differences, besides
drug use, may be responsible for the effects observed
here cannot be ruled out (although we attempted to
control for many of these, including ﬂuid intelligence
and perceived workload). Furthermore, self-reports of
background drug use are problematic due to recall of
quantities and frequencies, etc. not being entirely ac-
curate, not least given the implications for memory
deﬁcits with drug use. However, due to the legal status
of the drug being investigated, this is the most appro-
priate method for attaining an estimate of lifetime drug
use and is the most commonly used method in the
literature investigating drug use and cognition
(Fox et al. 2001; Montgomery et al. 2005, 2010).
Additional uncertainty about purity of ecstasy tablets
consumed, as well as cocaine purity and cannabis
strength, cannot be assured. However, ecstasy tablets
collected from amnesty bins in nightclubs in the UK
have been reported to be approaching 100% purity
(Parrott, 2004). Nevertheless, if this is incorrect and
the purity is, in fact, much lower, then perhaps the
magnitude of the cognitive effects observed is even
more concerning (Montgomery et al. 2010). In the pres-
ent study, resources limited us to subjective conﬁrma-
tion of drug use and abstinence, and we concede that
an objective measure would be advantageous (e.g.
from hair or urine samples). Reliance on self-report
measures of drug use is common in this ﬁeld of re-
search, and there are many published studies that do
not report objective measures (e.g. Rodgers, 2000;
Fox et al. 2002; Montgomery et al. 2005). A comparison
of subjective versus objective measures of drug use
(Scholey et al. 2011) has recently shown that self-
reports of ecstasy use are consistent with objective
analysis of hair samples in ecstasy users. More re-
cently, research from our own laboratory suggests
that participants are adhering to our inclusion criteria
of drug abstinence (Roberts et al. 2013a,b); very
low levels of metabolites were found in the urine of
recent users and excluding these participants from
analysis did not affect the results. Thus, while we
have no reason to believe that sub-acute intoxication
would affect the results of the present study, future re-
search should seek to utilize an objective measure
of drug use.
The present study provides evidence of aberrant
neural functioning, in ecstasy polydrug users, in re-
lation to DLPFC oxygenated and deoxygenated hae-
moglobin. Reductions in the increase of oxygenated
haemoglobin to the inferior right DLPFC, as well as
the left inferior DLPFC, during a task that requires a
high mental workload suggest that ecstasy users
have changes in these networks that support higher-
level cognitive functioning. These changes may be
attenuating any observable behavioural differences.
These ﬁndings are in line with the literature suggesting
that such changes in blood ﬂow may be due to seroto-
nergic neurotoxicity in forebrain structures.
Acknowledgements
No external funding was received for this work.
Declaration of Interest
None.
10 C. A. Roberts et al.
Note
1 Due to small amounts of missing data on different
optodes, MANOVA was not appropriate for this analysis.
References
Ayaz H (2010). Functional near infrared spectroscopy based
brain computer interface. PhD Thesis, Drexel University,
Philadelphia, PA.
Ayaz H, Shewokis PA, Bunce S, Izzetoglu K, Willems B,
Onaral B (2012). Optical brain monitoring for operator
training and mental workload assessment. NeuroImage 59,
36–47.
Ayaz H, Shewokis PA, Curtin A, Izzetoglu M, Izzetoglu K,
Onaral B (2011). Using MazeSuite and functional near
infrared spectroscopy to study learning in spatial
navigation. Journal of Visualized Experiments 56, e3443.
Benningﬁeld MM, Cowan RL (2013). Brain serotonin
function in MDMA (ecstasy) users: evidence for persisting
neurotoxicity. Neuropsychopharmacology 38, 253–255.
Bosch OG, Wagner M, Jessen F, Kühn KU, Joe A, Seifritz E,
Maier W, Biersack HJ, Quednow BB (2013). Verbal
memory deﬁcits are correlated with prefrontal
hypometabolism in 18FDG PET of recreational MDMA
users. PLOS ONE 8, e61234.
Burgess AP, Venables L, Jones H, Edwards R, Parrott AC
(2011). Event related potential (ERP) evidence for selective
impairment of verbal recollection in abstinent recreational
methylenedioxymethamphetamine (‘ecstasy’)/polydrug
users. Psychopharmacology 216, 545–556.
Chang L, Grob CS, Ernst T, Itti L, Mishkin FS,
Jose-Melchor R, Poland RE (2000). Effect of ecstasy
[3,4-methylenedioxymethamphetamine (MDMA)] on
cerebral blood ﬂow: a co-registered SPECT and MRI study.
Psychiatry Research 98, 15–28.
Cui X, Bray S, Reiss AL (2010). Functional near infrared
spectroscopy (NIRS) signal improvement based on
negative correlation between oxygenated and
deoxygenated hemoglobin dynamics. NeuroImage 49,
3039–3046.
Curtis CE, D’Esposito M (2003). Persistent activity in the
prefrontal cortex during working memory. Trends in
Cognitive Sciences 7, 415–423.
Ehlis A-C, Bahne CG, Jacob CP, Herrmann MJ, Fallgatter AJ
(2008). Reduced lateral prefrontal activation in adult
patients with attention-deﬁcit/hyperactivity disorder
(ADHD) during a working memory task: a functional
near-infrared spectroscopy (fNIRS) study. Journal of
Psychiatric Research 42, 1060–1067.
Erritzoe D, Frokjaer VG, Holst KK, Christoffersen M,
Johansen SS, Svarer C, Madsen J, Rasmussen PM,
Ramsøy T, Jernigan TL, Knudsen GM (2011). In vivo
imaging of cerebral serotonin transporter and serotonin2A
receptor binding in 3,4-methylenedioxy-methamphetamine
(MDMA or ‘ecstasy’) and hallucinogen users. Archives of
General Psychiatry 68, 562–576.
Evers EAT, Cools R, Clark L, van der Veen FM, Jolles J,
Sahakian BJ, Robbins TW (2005). Serotonergic modulation
of prefrontal cortex during negative feedback in
probabilistic reversal learning. Neuropsychopharmacology 30,
1138–1147.
Firbank M, Okada E, Delpy DT (1998). A theoretical study of
the signal contribution of regions of the adult head to
near-infrared spectroscopy studies of visual evoked
responses. NeuroImage 8, 69–78.
Fisk JE, Montgomery C, Hadjiefthyvoulou F (2011).
Visuospatial working memory impairment in current and
previous ecstasy/polydrug users. Human
Psychopharmacology 26, 313–321.
Fisk JE, Montgomery C, Murphy P, Wareing M (2004).
Evidence for executive deﬁcits among users of MDMA
(ecstasy). British Journal of Psychology 95, 457–466.
Fox HC, Parrott AC, Turner JJD (2001). Ecstasy use: cognitive
deﬁcits related to dosage rather than self-reported
problematic use of the drug. Journal of Psychopharmacology
15, 273–281.
Fox HC, McLean A, Turner JJD, Parrott AC, Rogers R,
Sahakian BJ (2002). Neuropsychological evidence of a
relatively selective proﬁle of temporal dysfunction in drug-
free MDMA (‘ecstasy’) polydrug users. Psychopharmacology
162, 203–214.
Gouzoulis-Mayfrank M, Daumann J (2009). Neurotoxicity of
drugs of abuse – the case of methylenedioxy amphetamines
(MDMA, ecstasy), and amphetamines. Dialogues in Clinical
Neuroscience 11, 305–317.
Green AR, Cross AJ, Goodwin GM (1995). Review of the
pharmacology and clinical pharmacology of
3,4-methylenedioxy-methamphetamine (MDMA or
‘Ecstasy’). Psychopharmacology 119, 247–260.
Green AR, Mechan AO, Elliot JM, O’Shea E, Colado MI
(2003). The pharmacology and clinical pharmacology of
3,4-methylenedioxy-methamphetamine (MDMA, ‘ecstasy’).
Pharmacological Reviews 55, 463–508.
Hart SG, Staveland LE (1988). Development of NASA-TLX
(Task Load Index): results of empirical and theoretical
research. In Human Mental Workload (ed. P. A. Hancock and
N. Meshkati) pp. 239–250 North Holland Press:
Amsterdam.
Hoshi Y, Kobayashi N, Tamura M (2001). Interpretation of
near-infrared signals: a study with newly developed
perfused rat brain model. Journal of Applied Physiology 90,
1657–1662.
Izzetoglu K, Bunce S, Onaral B, Pourrezaei K, Chance B
(2004). Functional optical brain imaging using near-infrared
during cognitive tasks. International Journal of
Human-Computer Interaction 17, 211–227.
Jager G, de Win MML, van der Tweel I, Schilt T, Kahn RS,
van den Brink W, van Ree JM, Ramsey NF (2008).
Assessment of cognitive brain function in ecstasy users
and contributions of other drugs of abuse: results from an
fMRI study. Neuropsychopharmacology 33, 247–258.
Kalechstein AD, De La Garza R II, Mahoney JJ III,
Fantegrossi WE, Newton TF (2007). MDMA use and
neurocognition: a meta-analytic review. Psychopharmacology
189, 531–537.
Kanayama G, Rogowska J, Pope HG, Gruber SA,
Yurglun-Todd DA (2004). Spatial working memory in
Prefrontal blood oxygenation during a demanding task in ecstasy users 11
heavy cannabis users: a functional magnetic resonance
imaging study. Psychopharmacology 176, 239–247.
Kish SJ, Lerch J, Furukawa Y, Tong J, McCluskey T,
Wilkins D, Houle S, Meyer J, Mundo E, Wilson AA,
Rusjan PM, Saint-Cyr JA, Guttman M, Collins DL,
Shapiro C, Warsh JJ, Boileau I (2010). Decreased cerebral
cortical serotonin transporter binding in ecstasy users: a
positron emission tomography/[11C]DASB and structural
brain imaging study. Brain 133, 1779–1797.
Leff DR, Elwell CE, Orihuela-Espina F, Atallah L,
Delpy DT, Darzi AW, Yang GY (2008). Changes in
prefrontal cortical behaviour depend upon familiarity on a
bimanual co-ordination task: an fNIRS study. NeuroImage
39, 805–813.
Leff DR, Orihuela-Espina F, Elwell CE, Athanasiou T,
Delpy DT, Darzi AW, Yand G-Z (2011). Assessment of the
cerebral cortex during motor task behaviours in adults: a
systematic review of functional near infrared spectroscopy
(fNIRS) studies. NeuroImage 54, 2922–2936.
McCann UD, Ridenour A, Shaham Y, Ricaurte GA (1994).
Serotonin neurotoxicity after
3,4-methelenedioxymethamphetamine (MDMA; ‘ecstasy’):
a controlled study in humans. Neuropsychopharmacology 10,
129–138.
McDowell DM, Kleber HD (1994). MDMA: its history and
pharmacology. Psychiatric Annals 24, 127–130.
Montgomery C, Fisk JE (2008). Ecstasy-related deﬁcits in the
updating component of executive processes. Human
Psychopharmacology 23, 495–511.
Montgomery C, Fisk JE, Newcombe R, Murphy PN (2005).
The differential effects of ecstasy/polydrug use on executive
components: shifting, inhibition, updating and access to
semantic memory. Psychopharmacology 182, 262–276.
Montgomery C, Hatton PN, Fisk JE, Ogden RS, Jansari A
(2010). Assessing the functional signiﬁcance of
ecstasy-related memory deﬁcits using a virtual
paradigm. Human Psychopharmacology 25, 318–325.
Parrott AC (2004). Is ecstasy MDMA? A review of the
proportion of ecstasy tablets containing MDMA, their
dosage levels, and the changing perceptions of purity.
Psychopharmacology (Berlin) 173, 234–241.
Parrott AC (2013). MDMA, serotonergic neurotoxicity, and
the diverse functional deﬁcits of recreational ‘ecstasy’ users.
Neuroscience and Biobehavioral Reviews 37, 1466–1484.
Parrott AC, Lasky J (1998). Ecstasy (MDMA) effects upon
mood and cognition: before, during and after a Saturday
night dance. Psychopharmacology 139, 261–268.
Parrott AC, Sisk E, Turner JJD (2000). Psychobiological
problems in heavy ‘ecstasy’ (MDMA) polydrug users. Drug
and Alcohol Dependence 60, 105–110.
Pazos A, Prosbit A, Palacios JM (1987). Serotonin receptors in
the human brain – III. Autoradiographic mapping of
serotonin-1 receptors. Neuroscience 21, 97–122.
Raven J, Raven JC, Court HH (1998). Manual for Raven’s
Progressive Matrices and Vocabulary Scales. Oxford
Psychologists Press: Oxford, UK.
Reneman L, Habraken JBA, Majoie CBL, Booij J,
den Heeten GJ (2000). MDMA (‘ecstasy’) and its
association with cerebrovascular accidents: preliminary
ﬁndings. American Journal of Neuroradiology 21, 1001–1007.
Reneman L, Schilt T, de Win MM, Booij J, Schmand B,
van den Brink W, Bakker O (2006). Memory function
and serotonin transporter promoter gene polymorphism in
ecstasy (MDMA) users. Psychopharmacology 20, 389–399.
Robbins TW, Arnsten AF (2009). The
neuropsychopharmacology of fronto-executive function:
monoaminergic modulation. Annual Review of Neuroscience
32, 267–287.
Roberts C, Fairclough S, Fisk JE, Tames F, Montgomery C
(2013a). Electrophysiological indices of response inhibition
in human polydrug users. Journal of Psychopharmacology 27,
779–789.
Roberts CA, Fairclough SF, Fisk JE, Tames F, Montgomery C
(2013b). ERP evidence suggests executive dysfunction in
ecstasy polydrug users. Psychopharmacology 3, 375–388.
Rodgers J (2000). Cognitive performance amongst recreational
users of ‘ecstasy’. Psychopharmacology 151, 19–24.
Rodgers J, Buchanan T, Scoley AB, Heffernan TM, Ling J,
Parrott AC (2003). Patterns of drug use and the inﬂuence of
gender on self reports of memory ability in ecstasy users: a
web based study. Journal of Psychopharmacology 17, 389–396.
Sankoh AJ, Huque MF, Dubey SD (1997). Some comments
on frequently used multiple endpoint adjustment methods
in clinical trials. Statistics in Medicine 16, 2529–2542.
Schecklmann M, Ehlis AC, Plichta MM, Romanos J,
Heine M, Boreatti-Hümmer A, Jacob C, Falgatter AJ
(2008). Diminished prefrontal oxygenation with normal
and above-average verbal ﬂuency performance in adult
ADHD. Journal of Psychiatric Research 43, 98–106.
Scholey AB, Owen L, Gates J, Rodgers J, Buchanan T,
Ling J, Heffernan T, Swan P, Stough C, Parrott AC
(2011). Hair MDMA samples are consistent with reported
ecstasy use: ﬁndings from a study investigating effects
of Ecstasy on mood and memory. Neuropsychobiology 63,
15–21.
Taussky P, O’Neal B, Daugherty WP, Luke S, Thorpe D,
Pooley RA, Evans C, Hanel RA, Freeman WD (2012).
Validation of frontal near-infrared spectroscopy as
noninvasive bedside monitoring for regional cerebral blood
ﬂow in brain-injured patients. Neurosurgical Focus 32, E2.
Wareing M, Murphy PN, Fisk JE (2004). Visuospatial
memory impairments in users of MDMA (‘ecstasy’).
Psychopharmacology 173, 391–397.
Wetherell MA, Atherton K, Grainger J, Brosnan R,
Scholey AB (2012). The effects of multitasking on
psychological stress reactivity in recreational users of
cannabis and MDMA. Human Psychopharmacology: Clinical
and Experimental 27, 167–176.
Wetherell MA, Sidgreaves MC (2005). Short communication:
secretory immunoglobulin – a reactivity following increases
in workload intensity using the Deﬁned Intensity Stressor
Simulation (DISS). Stress and Health 21, 99–106.
Zakzanis KK, Campbell Z, Jovanovski D (2007). The
neuropsychology of ecstasy (MDMA) use: a quantitative
review. Human Psychopharmacology: Clinical and
Experimental 22, 427–435.
12 C. A. Roberts et al.
